When to thin blood after brain bleed? new trial seeks answer
NCT ID NCT06753786
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 200 people who had a bleeding stroke caused by high blood pressure. Doctors want to know if starting blood thinners (heparin) early—within 2 days—or waiting until day 3 is safer and better at preventing blood clots in the legs or lungs. Participants get brain scans and leg ultrasounds to check for clot formation or bleeding expansion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
heparin (unfractionated or low molecular weight)
What this could lead to
If successful, this could establish the safest time to start blood thinners in bleeding stroke patients to prevent dangerous clots without worsening brain bleeding.
What could go wrong
This is a single-center trial with 200 participants, so results may not apply broadly. Both timing strategies carry bleeding risks, and the study may not find a clear winner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moscow City Clinical Hospital named after V.M. Buyanov
RECRUITINGMoscow, 115516, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••